Firstly, FOLFOX-Bev treatment may kill sensitive cancer cells that primarily secrete VEGFB, leading to compensatory upregulation of VEGFA in the remaining insensitive cancer cells, which is competitively bound by bevacizumab, thereby dually inhibiting the VEGF pathway. The gene discussed is VEGFA; the disease is cancer.